- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xenon Pharmaceuticals Inc (XENE)Xenon Pharmaceuticals Inc stock price live, this page displays NASDAQ XENE stock exchange data. View the XENE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xenon Pharmaceuticals Inc real time stock price chart below.
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 42.72.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock symbol for Xenon Pharmaceuticals Inc is "XENE."
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 42.72.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock symbol for Xenon Pharmaceuticals Inc is "XENE."
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
42.72
+1.31(+3.16%)
Closed
After Hours
42.720.00(0.00%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.37
42.77
52 wk Range
35.53
50.99
XENE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.3742.77
52 wk Range
35.5350.99
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
XENE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
57.18
Upside
+33.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc SWOT Analysis
Azetukalner's Promise | Xenon's lead drug candidate shows potential in epilepsy and major depressive disorder, with pivotal Phase III trials underway and expansion into new markets |
Clinical Milestones | Key readouts expected in 2025 could significantly impact Xenon's valuation, with analysts anticipating increased investor interest as trial results approach |
Market Opportunity | Analysts estimate a combined commercial potential exceeding $1 billion for azetukalner in epilepsy and MDD, highlighting substantial growth prospects |
Analyst Perspectives | RBC Capital Markets maintains an Outperform rating with a $55.00 price target, reflecting confidence in Xenon's clinical progress and market potential |
XENE Full Pro Research
Institutional-Grade Stock Analysis
Understand how XENE earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Xenon Pharmaceuticals Inc Earnings Call Summary for Q3/2024
- Strong cash position of $850.6M, supporting operations into 2027; IND filing for lead candidates expected in 2025
- Phase 3 trials for azetukalner in epilepsy progressing; MDD program to initiate in H2 2024
- Positive clinical data and feedback for azetukalner in epilepsy and MDD; exploring new indications with next-gen ion channel modulators
- SCN8A Phase 2 trial for focal-onset seizures missed expectations; late-stage plan for Nav1.7 in pain undetermined
- Focus on U.S. sites for Phase 3 trials; partnership with Neurocrine for new Nav1.6 and Nav1.2 targeting molecule in epilepsy
Last Updated: 10-08-2024, 06:44 pm
Read Full TranscriptCompare XENE to Peers and Sector
Metrics to compare | XENE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXENEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.3x | −4.7x | −0.7x | |
PEG Ratio | 2.86 | −0.09 | 0.00 | |
Price/Book | 4.1x | −0.7x | 2.6x | |
Price / LTM Sales | - | 0.8x | 3.2x | |
Upside (Analyst Target) | 38.0% | 634.0% | 46.6% | |
Fair Value Upside | Unlock | −3.3% | 7.4% | Unlock |
Analysts' Recommendations
17 Buy
0 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 57.18
(+33.85% Upside)
FAQ
What Is the Xenon Pharmaceuticals (XENE) Stock Price Today?
The Xenon Pharmaceuticals stock price today is 42.72.
What Stock Exchange Does Xenon Pharmaceuticals Trade On?
Xenon Pharmaceuticals is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Xenon Pharmaceuticals?
The stock symbol for Xenon Pharmaceuticals is "XENE."
What Is the Xenon Pharmaceuticals Market Cap?
As of today, Xenon Pharmaceuticals market cap is 3.26B.
What is Xenon Pharmaceuticals Earnings Per Share?
The Xenon Pharmaceuticals EPS is -2.82.
What Is the Next Xenon Pharmaceuticals Earnings Date?
Xenon Pharmaceuticals will release its next earnings report on 25 Feb 2025.
From a Technical Analysis Perspective, Is XENE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.